Oncorena

Oncorena is pioneering a novel therapeutic approach for metastatic kidney cancer by leveraging orellanine, a naturally occurring fungal toxin known for its specific nephrotoxicity. The company's strategy involves initially treating dialysis-dependent patients to mitigate renal safety risks while demonstrating anti-tumor efficacy. With its lead program, ONC175, in active Phase I/II trials and recent regulatory approvals in the US and Europe, Oncorena is advancing a potentially transformative therapy for a patient population with high unmet need. The company is privately held and has recently secured significant funding to support clinical development.

Repurposing of synthetic orellanine, a kidney-specific fungal toxin, as a targeted cytotoxic therapy for renal cell carcinomas based on its inherent renal tropism.

ONC175 is a first-in-class candidate with no direct competitors targeting renal cancer via this specific toxin mechanism. However, it operates in the crowded metastatic RCC space dominated by TKIs, immunotherapy combinations, and other novel agents. Its differentiation lies in its kidney-specific targeting, potentially offering a unique efficacy/side-effect profile compared to systemic therapies.